Clinical trial Archives

News and Trends 13 Dec 2022

Ascletis announces positive COVID-19 trial results

Ascletis Pharma Inc. has announced positive topline results from its phase I multiple ascending dose (MAD) study in healthy subjects for oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 treatment. Ascletis’ ASC10 is an innovative orally available double prodrug, which has a new and differentiated chemical structure from the single prodrug molnupiravir. After oral […]

December 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Poolbeg influenza trial successfully completed

Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […]

December 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 12 Dec 2022

Enterome completes patient enrollment for recurrent glioblastoma study

Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […]

December 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

New targeted drug shows benefit against breast cancer in first phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […]

December 9, 2022 - 7 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

PDCline Pharma presents first immunological results from trial with PDClung01

PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […]

December 8, 2022 - 3 minutesmins - By Liza Laws

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Dec 2022

MetrioPharm reveals COVID-19 study data

MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. In the trial, patients received either MP1032 plus standard of care (SoC), or placebo plus SoC. SoC partially included other antivirals (Remdesivir or Nirmatrelvir/Ritonavir), […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Novadip bone healing trial yields positive results

Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003. The study was on patients with severe bone non-union (BNU) of the lower limb following trauma. Novadip is a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to […]

December 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Owlstone Medical launches Breath Biopsy AOC Atlas built with diverse breath samples

Owlstone Medical, a U.K. company working in breath biopsy for applications in early disease detection and precision medicine has announced the launch of the Breath Biopsy AOC Atlas. This is a catalogue of volatile organic compounds (VOCs) found on breath. The Atlas provides insight and scientific context into the molecules, supporting biomarker discovery through incorporation […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

Rani Therapeutics reveals results from phase 1 osteoporosis study

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of […]

December 7, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Ascletis announces positive COVID-19 trial results

Poolbeg influenza trial successfully completed

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Enterome completes patient enrollment for recurrent glioblastoma study

New targeted drug shows benefit against breast cancer in first phase III trial

PDCline Pharma presents first immunological results from trial with PDClung01

Enhertu’s positive results demonstrate improvement in overall survival

MetrioPharm reveals COVID-19 study data

Novadip bone healing trial yields positive results

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

Owlstone Medical launches Breath Biopsy AOC Atlas built with diverse breath samples

Rani Therapeutics reveals results from phase 1 osteoporosis study

Subscribe to our newsletter to get the latest biotech news!